Use experience of tolvaptan for end stage liver disease waiting for liver transplantation.

Use experience of tolvaptan for end stage liver disease waiting for liver transplantation. - Use experience of tolvaptan for end stage liver disease waiting for liver transplantation.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027096

Enrollment

Registered

2017-04-21

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients in end stage liver disease who was complicated by refractory ascites and was adaptive for liver transplantation

Exclusion criteria

Exclusion criteria: 1.poor oral intake 2.past history to administrate tolvaptan 3.rejection by patients

Design outcomes

Primary

Measure	Time frame
change of body weight after initiation	—

Secondary

Measure	Time frame
urine volume,total-bilirubin,creatinine,sodium,Child-Pugh score,MELD score,Clavien-Dindo score,post operative day,readmission	—

Countries

Japan

Contacts

Public ContactSho Kiritani

The University of Tokyo Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine

sho.kiritani@gmail.com0338155411

Outcome results